|
However, the company reiterated that it would file the report
with U.S. and Canadian regulators on or before June 10, ahead of
a July 31 deadline.
Valeant has lost more than half its value since mid-March, after
it said a delay in the filing of its annual report could put it
at risk of a default on its borrowings.
The Laval, Quebec based company is also facing mounting scrutiny
from the U.S. Congress, prosecutors and regulators over its drug
pricing, business practices and accounting, issues that have
pushed its shares down nearly 89 percent since August.
(Reporting by Natalie Grover in Bengaluru; Editing by Anil
D'Silva)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
